logo

BIVI

BioVie·NASDAQ
--
--(--)
--
--(--)
4.54 / 10
Netural

BioVie's fundamentals are mixed: positive aspects include a solid interest-coverage ratio (42.48%) and robust revenue growth (64.39% YoY). However, significant headwinds remain, such as a high days-sales-outstanding (313.91) and a negative revenue-to-market value (-0.257), signaling collection inefficiencies and valuation concerns. Net income is still below revenue (-0.166), and the PB-ROE ratio (0.374) is only moderate. These factors collectively place the company in a Neutral fundamental stance.

Fundamental(4.54)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-0.26
Score3/3
Weight17.37%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value45.97
Score2/3
Weight1.48%
1M Return1.11%
Days sales outstanding
Value313.91
Score1/3
Weight-1.91%
1M Return-1.57%
Profit-MV
Value0.46
Score2/3
Weight13.85%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight13.86%
1M Return8.45%
PB-ROE
Value0.37
Score1/3
Weight16.86%
1M Return9.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value42.48
Score2/3
Weight-1.39%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value64.40
Score2/3
Weight0.57%
1M Return0.43%
Asset-MV
Value-1.35
Score3/3
Weight25.68%
1M Return13.15%
Cash-MV
Value-0.07
Score2/3
Weight13.62%
1M Return8.41%
Is BIVI undervalued or overvalued?
  • BIVI scores 4.54/10 on fundamentals and holds a Fair valuation at present. Backed by its -23.36% ROE, 0.00% net margin, -0.48 P/E ratio, 0.34 P/B ratio, and 88.00% earnings growth, these metrics solidify its Netural investment rating.